FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...
FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda. Agilent Technologies Inc. announced that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results